Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic lymphocytic leukemia and non-Hodgkin's lymphoma in adult Russian patients

American Journal of Hematology

Volumn 83, Issue 4, 2008, Pages 279-287

  Gra, Olga A ^a   Glotov, Andrey S ^a,b   Nikitin, Eugene A ^c   Glotov, Oleg S ^b   Kuznetsova, Viktoria E ^a   Chudinov, Alexander V ^a   Sudarikov, Andrey B ^c   Nasedkina, Tatyana V ^a  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^b D O OTT RESEARCH INSTITUTE OF OBSTETRICS   (Russian Federation)

^c NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ARYLAMINE ACETYLTRANSFERASE; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; METHIONINE SYNTHASE; PLASMA PROTEIN; PROTEIN NQ09; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; B CELL LYMPHOMA; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DNA HYBRIDIZATION; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR; RUSSIAN FEDERATION; SEX DIFFERENCE; T CELL LYMPHOMA; XENOBIOTIC METABOLISM;

ADULT; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; BIOTRANSFORMATION; CARCINOGENS, ENVIRONMENTAL; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; FERREDOXIN-NADP REDUCTASE; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, T-CELL; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); NAD(P)H DEHYDROGENASE (QUINONE); NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RISK FACTORS; RUSSIA; XENOBIOTICS;

EID: 41449112154     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21113     Document Type: Article

References (53)

1. Wood ME, Bunn PA. Hematclogy/oncology secrets. Philadelphia: Hanley & Belfus Inc; 1994. pp 175-180.
2. Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology 2004;163-183.
3. Grulich AE, Vajdic CM. The epidemiology of non-Hodgkin lymphoma. Pathology 2005;37:409-419.
4. Houlston RS, Sellick G, Yuille M, et al. Causation of chronic lymphocytic leukemia - insights from familial disease. Leuk Res 2003;27:871-876. Review.
5. Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: Results from the Swedish Family-Cancer Database. Blood 2004;104:1850-1854.
6. Goldin LR, Landgren O, McMaster ML, et al. Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samples. Cancer Epidemiol Biomarkers Prev 2005;14:2402-2406.
7. Chang ET, Smedby KE, Hjalgrim H, et al. Family history of hematopoietic malignancy and risk of lymphoma. J Natl Cancer Inst 2005;97:1466-1474.
8. Sellick GS, Webb EL, Allinson R, et al. A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci. Am J Hum Genet 2005;77:420-429.
9. Ng D, Toure O, Wei MH, et al. Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia. Blood 2007;109:916-925.
10. Engels EA. Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2007;16:401-404.
11. Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica 2007;92:960-969.
12. Rudd MF, Sellick GS, Webb EL, et al. Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia. Blood 2006;108:638-644.
13. Rothman N, Skibola CF, Wanç SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lympioma: A report from the InterLymph Consortium. Lancet Oncol 2006;7:27-38.
14. Skibola CF, Forrest MS, Coppedé F, et al. Polymorphisms and haplotypes in folate-metabolizing genes and risk of non-Hodgkin lymphoma. Blood 2004;104:2155-2162.
15. Niclot S, Pruvot Q, Besson C, et al. Implication of the folate-methionine metabolism pathways in susceptibility to follicular lymphomas. Blood 2006;108:278-285.
16. Matsuo K, Hamajima N, Suzuki R, et al. Methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms and reduced risk of malignant lymphoma. Am J Hematol 2004;77:351-357.
17. Rudd MF, Sellick GS, Allinson R, et al. MTHFR polymorphisms and risk of chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 2004;13:2268-2270.
18. Maiorova OA, Netrebenko OK, Shumilov PV. Effect of polymorphic enzymatic systems on development of oncological processes (nutritiological aspects). Pediatr Haematol/Oncol Immunopathol 2003;2:45-48.
19. Roddam PL, Rollinson S, Kane E, et al. Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are ai increased risk of developing adult acute leukaemia. Pharmacogenetics 2000;10:605-615.
20. Baranov VS, Ivashchenko TE, Baranova EV. Genomics and pharmacogenetics in prevention and treatment of some common diseases in children. Curr Pediatr 2004;3:57-61.
21. Krajinovic M, Labuda D, Richer C, et al. Susceptibility to childhood acute lymphoblastic leukemia: Influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999;93:1496-1501.
22. D'Alo F, Voso MT, Guidi F, et al. Polymorphisms of CYP1A1 and glutathione S-transferase and susceptibility to adult acute myeloid leukemia. Haematologica 2004;89:664-670.
23. Aydin-Sayitoglu M, Hatirnaz O, Erensoy N, Ozbek U. Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias. Am J Hematol 2006;81:162-170.
24. Balta G, Yuksek N, Ozyurek E, et al. Characterization of MTHFR, GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes in childhood acute leukemia. Am J Hematol 2003;73:154-160.
25. Pakakasama S, Mukda E, Sasanakul W, et al. Polymorphisms of drug-metabolizing enzymes and risk of childhood acute lymphoblastic leukemia. Am J Hematol 2005;79:202-205.
26. Lemos MC, Cabrita FJ, Silva HA, et al. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis 1999;20:1225-1229.
27. Sarmanová J, Benesová K, Gut I, et al. Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas. Hum Mol Genet 2001;10:1265-1273.
28. Kerridge I, Lincz L, Scorgie F, et al. Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Br J Haematol 2002;118:477-481.
29. Chiu BC, Kolar C, Gapstur SM, et al. Association of NAT and GST polymorphisms with non-Hodgkin's lymphoma: A population-based case-control study. Br J Haematol 2005;128:610-615.
30. Yuille M, Condie A, Hudson C, et al. Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia. Blood 2002;99:4216-4218.
31. Hohaus S, Massini G, D'Alo F, et al. Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis. Clin Cancer Res 2003;9:3435-3440.
32. Tsabouri S, Georgiou I, Katsaraki A, Bourantas KL. Glutathione sulfur transferase M1 and T1 genotypes in chronic lymphoblastic leukemia. Hematol J 2004;5:500-504.
33. Glotov AS, Nasedkina TV, Ivashchenko TE, et al. Biochip development for polymorphism analysis in biotransformation system genes. Mol Biol (Mosk) 2005;39:403-412.
34. Botto N, Andreassi MG, Manfredi S, et al. Genetic polymorphisms in folate and homocysteine metabolism as risk factors for DNA damage. Eur J Hum Genet 2003;11:671-678.
35. Niclot S, Pruvot Q, Besson C, et al. Implication of the folate-methionine metabolism pathways in susceptibility to follicular lymphomas. Blood 2006;108:278-285.
36. Shimada T. Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab Pharmacokinet 2006;21:257-276.
37. Schwarz D, Kisselev P, Cascorbi I, et al. Differential metabolism of benzo[a]-pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants. Carcinogenesis 2001;22:453-459.
38. Georgiadis P, Topinka J, Vlachodimitropoulos D, et al. Interactions between CYP1A1 polymorphisms and exposure to environmental tobacco smoke in the modulation of lymphocyte bulky DNA adducts and chromosomal aberrations. Carcinogenesis 2005;26:93-101.
39. Krajinovic M, Labuda D, Mathonnet G, et al. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res 2002;8:802-810.
40. Sterling KM Jr, Cutroneo KR. Constitutive and inducible expression of cytochromes P4501A (CYP1A1 and CYP1A2) in normal prostate and prostate cancer cells. J Cell Biochem 2004;91:423-429.
41. Lin P, Chang JT, Ko JL, et al. Reduction of androgen receptor expression by benzo[alpha]pyrene and 7,8-dihydro-9,10-epoxy-7,8,9,10-tetrahydrobenzo [alpha]pyrene in human lung cells. Biochem Pharmacol 2004;67:1523-1530.
42. Kuil CW, Brouwer A, van der Saag PT, van der Burg B. Interference between progesterone and dioxin signal transduction pathways. Different mechanisms are involved in repression by the progesterone receptor A and B isoforms. J Biol Chem 1998;273:8829-8834.
43. Bartsch H, Rojas M, Nair U, et al. Genetic cancer susceptibility and DNA adducts: Studies in smokers, tobacco chewers, and coke oven workers. Cancer Detect Prev 1999;23:445-53.
44. Wasserman WW, Fahl WE. Functional antioxidant responsive elements. Proc Natl Acad Sci USA 1997;94:5361-5366.
45. Ansell PJ, Espinosa-Nicholas C, Curran EM, et al. In vitro and in vivo regulation of antioxidant response element-dependent gene expression by estrogens. Endocrinology 2004;145:311-317.
46. Waxman DJ. P450 gene induction by structurally diverse xenochemicals: Central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 1999;369:11-23. Review.
47. Honkakoski P, Sueyoshi T, Negishi M. Drug-activated nuclear receptors CAR and PXR. Ann Med 2003;35:172-182.
48. Forman BM, Tzameli I, Choi HS, et al. Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature 1998;395:612-615.
49. Chan AT, Tranah GJ, Giovannucci EL, et al. A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma. Clin Gastroenterol Hepatol 2004;2:704-712.
50. Joseph T, Kusumakumary P, Chacko P, et al. Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children. Pediatr Blood Cancer 2004;43:560-567.
51. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Hematol J 2000;1:53-66.
52. Rubina AY, Pan'kov SV, Dementieva EI, et al. Hydrogel drop microchips with immobilized DNA: Properties and methods for large-scale production. Anal Biochem 2004;325:92-106.
53. Nasedkina TV, Fedorova OE, Glotov AS, et al. Rapid genotyping of common deficient thiopurine S-methyltransferase alleles using the DNA-microchip technique. Eur J Hum Genet 2006;14:991-998.